每经AI快讯,5月21日,诺诚健华公告称,公司收到国家药品监督管理局的通知,公司靶向CD19的产品坦昔妥单抗(tafasitamab)联合来那度胺治疗不适合自体干细胞移植条件的复发/难治性弥漫性大B细胞淋巴瘤(r/rDLBCL)成人患者的上市申请获得批准,这是中国首个获批治疗r/rDLBCL的CD19单抗。该药品的获批将丰富公司的商业化产品种类,并巩固公司在血液瘤领域的地位。(文章来源:每日经济...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.